Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026
Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026
Company Drug

Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC

Fineline Cube Aug 23, 2022

Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...

Company Deals

Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate

Fineline Cube Aug 22, 2022

Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...

Company

InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales

Fineline Cube Aug 22, 2022

China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...

Company Deals

Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform

Fineline Cube Aug 22, 2022

Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...

Company Drug

Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China

Fineline Cube Aug 22, 2022

China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...

Company

Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial

Fineline Cube Aug 22, 2022

Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...

Company

Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B

Fineline Cube Aug 22, 2022

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022,...

Company Deals

JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products

Fineline Cube Aug 22, 2022

JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series...

Company Drug

IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China

Fineline Cube Aug 22, 2022

China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...

Company

Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions

Fineline Cube Aug 22, 2022

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC

Fineline Cube Aug 22, 2022

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer

Fineline Cube Aug 19, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd,...

Policy / Regulatory

NHSA Proposes Regulations to Standardize Oral Implant Charges and Reduce Costs

Fineline Cube Aug 19, 2022

The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying...

Company Digital

Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth

Fineline Cube Aug 19, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company

WuXi STA Breaks Ground on New US Manufacturing Site in Delaware

Fineline Cube Aug 19, 2022

WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...

Company Deals

ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...

Company Drug

Zhejiang Erying’s Acetaminophen Set for CDE Priority Review in Pediatric Fever and Pain

Fineline Cube Aug 19, 2022

The Center for Drug Evaluation (CDE) has indicated that Zhejiang Erying Pharmaceutical Co., Ltd’s acetaminophen...

Company

Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing

Fineline Cube Aug 19, 2022

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...

Company Deals

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development

Fineline Cube Aug 19, 2022

LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...

Company Drug

Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China

Fineline Cube Aug 19, 2022

Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...

Posts pagination

1 … 633 634 635 … 665

Recent updates

  • Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
  • Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
  • Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
  • Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
  • Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.